ClinicalTrials.gg
CompletedNCT04305899Updated Nov 11, 2021

A Study to Compare the Taste and Levels in Blood Plasma of BMS-986165 When Taken as Different Formulations by Healthy Adult Participants

A Phase 1 interventional study of BMS-986165 Tablet formulation 1 and BMS-986165 Tablet formulation 2 in Healthy Participants, sponsored by Bristol-Myers Squibb. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-11-11.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Nov 2020, 5 years 11 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to compare the taste, and the levels in blood plasma of different tablet formulations of BMS-986165 when taken by healthy adults.

02

Conditions studied

  • Healthy Participants
03

In context

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion criteria

Inclusion Criteria:

  • Healthy participants, as determined by no deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations in the opinion of the investigator
  • Women and men must agree to follow specific methods of , if applicable

Exclusion criteria

Exclusion Criteria:

  • Any significant acute or chronic medical condition that presents a potential risk to the participant and/or may compromise the objectives of the study, including a history of/or active liver disease
  • Inability to tolerate oral medication
  • History of allergy to BMS-986165 or related compounds

Other protocol-defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Treatment Group 1

    Drug: BMS-986165 Tablet formulation 1 · Drug: BMS-986165 Tablet formulation 2

  • Experimental
    Treatment Group 2

    Drug: BMS-986165 Tablet formulation 1 · Drug: BMS-986165 Tablet formulation 2

  • Experimental
    Treatment Group 3

    Drug: BMS-986165 Tablet formulation 1 · Drug: BMS-986165 Tablet formulation 2

  • Experimental
    Treatment Group 4

    Drug: BMS-986165 Tablet formulation 1 · Drug: BMS-986165 Tablet formulation 2

  • Experimental
    Treatment Group 5

    Drug: BMS-986165 Tablet formulation 1 · Drug: BMS-986165 Tablet formulation 2

  • Experimental
    Treatment Group 6

    Drug: BMS-986165 Tablet formulation 1 · Drug: BMS-986165 Tablet formulation 2

  • Experimental
    Treatment Group 7

    Drug: BMS-986165 Tablet formulation 1 · Drug: BMS-986165 Tablet formulation 2

  • Experimental
    Treatment Group 8

    Drug: BMS-986165 Tablet formulation 1 · Drug: BMS-986165 Tablet formulation 2

  • Experimental
    Treatment Group 9

    Drug: BMS-986165 Tablet formulation 1 · Drug: BMS-986165 Tablet formulation 2

  • Experimental
    Treatment Group 10

    Drug: BMS-986165 Tablet formulation 1 · Drug: BMS-986165 Tablet formulation 2

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum concentration (Cmax) in plasma for BMS-986165

    Time frame: Up to 26 days

  2. Area under the plasma concentration-time curve from time 0 to the last quantifiable concentration (AUC(0-T)) in plasma for BMS-986165

    Time frame: Up to 26 days

  3. Area under the plasma concentration-time curve extrapolated to infinity (AUC(INF)) in plasma for BMS-986165

    Time frame: Up to 26 days

Secondary outcomes

  1. Incidence of Adverse Events (AEs)

    Time frame: Up to 26 days

  2. Incidence of Serious Adverse Events (SAEs)

    Time frame: Up to 98 days

  3. Incidence of clinically significant changes in physical examination findings

    Time frame: Up to 68 days

  4. Incidence of clinically significant changes in vital signs: Weight

    Time frame: Up to 68 days

  5. Incidence of clinically significant changes in vital signs: Body temperature

    Time frame: Up to 68 days

  6. Incidence of clinically significant changes in vital signs: Respiratory rate

    Time frame: Up to 68 days

  7. Incidence of clinically significant changes in vital signs: Blood pressure

    Time frame: Up to 68 days

  8. Incidence of clinically significant changes in vital signs: Heart rate

    Time frame: Up to 68 days

  9. Incidence of clinically significant changes in electrocardiogram (ECG) parameters

    Time frame: Up to 68 days

  10. Incidence of clinically significant changes in clinical laboratory results: Hematology tests

    Time frame: Up to 68 days

  11. Incidence of clinically significant changes in clinical laboratory results: Clinical chemistry tests

    Time frame: Up to 68 days

  12. Incidence of clinically significant changes in clinical laboratory results: Urinalysis tests

    Time frame: Up to 68 days

07

Study locations

1 site
  • PRA Health Sciences - Lenexa
    Lenexa, Kansas 66219, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2020 to primary completion in Nov 2020, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2020
First posted
Mar 12, 2020
StartActual
Aug 31, 2020
Primary completionActual
Nov 25, 2020
CompletionActual
Nov 25, 2020
Last update
Nov 11, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 11, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04305899
Responsible party
Sponsor
First posted
Mar 12, 2020
Start date
Aug 31, 2020
Primary completion
Nov 25, 2020
Completion
Nov 25, 2020
Last update
Nov 11, 2021

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Deucravacitinib

Start the discussion